Every anaesthetist in Australia and New Zealand would surely be familiar with a surgeon's injunction to 'give the patient a shot of gentamicin' which is commonly used for antibiotic prophylaxis, especially for urological procedures.
However, this practice needs to be re-evaluated in light of a recent paper by Ahmed et al 1 . In the largest series to date, they reported on 103 cases of gentamicin ototoxicity from a single Australian tertiary hospital. Nearly all patients presented with balance disorders (and not hearing loss, which is widely believed to be the main adverse effect of gentamicin). Twenty-one patients developed vestibular symptoms during a course of treatment, although this was recognised in only one patient at the time. Most patients developed symptoms after gentamicin administration had ceased, with a delay in diagnosis of 4 days to 15 years. Hence, although this case series spanned 23 years, the authors' speculation that this represented the 'tip of the iceberg' is justified.
Furthermore, a history of gentamicin administration may not be easily elicited or suspected as a cause of impaired balance in a frail, elderly patient following a hospital admission, increasing the likelihood of both missed diagnosis and misdiagnosis. The prescribing physicians are also likely to be unaware that their patient has suffered this complication unless litigation ensues (as has happened in Australia).
However, the most alarming finding from the study by Ahmed et al was that there was no 'safe dose' of gentamicin with respect to vestibulotoxicity, which could occur even when trough or peak serum concentrations were below recommended levels. In six patients it occurred following a single dose. This lack of an association between gentamicin dose and vestibulotoxicity had previously been identified in a smaller series of 33 patients 2 .
The mechanism by which gentamicin damages the vestibular system is unknown. Gentamicin is sequestered in the endolymph of the inner ear. One hypothesis is that gentamicin increases the release of oxygen free radicals, which damage hair follicles if there are inadequate free radical scavengers (such as glutathione) present 3 . This might explain the idiosyncratic nature of gentamicininduced vestibulotoxicity which, unlike most forms of drug toxicity, does not appear to be dose-related.
Some authors have questioned whether aminoglycoside antibiotics should be given at all 4 . This is because there are less toxic, alternative antibiotics that have equivalent or superior activity against gram-negative rods and Pseudomonas aeruginosa. However, gentamicin is still recommended in current therapeutic guidelines because it is effective (especially against gram-negative organisms) and less prone to the development of resistance than other antibiotics 5 . Nevertheless, its therapeutic use should only be used in seriously ill patients, when the organism is likely to be sensitive, and when there are no safer alternatives 1 .
We therefore need to ask ourselves, for each and every administration, whether our prophylactic use of gentamicin is appropriate. In the Ahmed et al series, gentamicin was given appropriately (ie. as per current Australian guidelines 5 ) in only 46% of patients. However, this series mostly comprised patients who received gentamicin for therapeutic rather than prophylactic indications (on which there are no local data).
It is likely that increasing awareness of the risks of gentamicin will reduce the indications for its use in future prescribing guidelines. It is worth noting that this is already happening in other parts of the world. For example, the American Urological Association no longer recommends gentamicin as a first-line antibiotic for endoscopic procedures, but as an alternative, second-line agent. Although it is still recommended as a first-line prophylactic antibiotic for open, laparoscopic or percutaneous procedures involving the kidney or urinary tract, there are other recommended first-line alternatives such as cephalosporins for most of these indications 6 .
Given its potential to cause severely disabling, permanent balance disorders, it is surely time that we broke our habit of giving gentamicin prophylaxis when it is either not indicated as a firstline agent, or when there are safer recommended alternatives available. This will involve negotiation with and education of our surgical colleagues. Failure to change this practice will unnecessarily expose our patients to the risk of severe injury, and ourselves to the risk of avoidable litigation.
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